Open Questions II
What is the variance between individuals in how drug levels vary over the day?
Is it the case that a balance needs to be struck between QD dosing, and hopefully improved adherence and potential increases in drug concentration variations?
To what degree do “host resistance” phenomena determine treatment effect e.g. does long term nucleoside treatment impair one’s ability to phosphorylate nucleosides?
Will parenteral-only treatments be accepted? Will compliance differ greatly from that of oral compounds? What will the virologic impact be?